Insights
Search Results
Client Highlights
4.21.22
Wilson Sonsini Advises Lead Investor Temasek on UPSIDE Foods' $400 Million Series C
On April 21, 2022, UPSIDE Foods (formerly Memphis Meats), a leading company in the cultivated meat, poultry, and seafood industry, announced the close of a $400 million Series C funding round that brings the company's valuation to over $1 billion. The Series C round was co-led by Temasek, a global investment company headquartered in Singapore, and the Abu Dhabi Growth Fund, a new investor. Other new investors include Baillie Gifford, Givaudan, John Doerr, SALT fund, and Synthesis Capital. They are joined by existing investors Bill Gates, Cargill, Cercano Management, CPT Capital, Dentsu Ventures, Singapore-based global investor EDBI, Kimbal and Christiana Musk, Norwest Venture Partners, SoftBank Vision Fund 2, SOSV's Indie Bio, and Tyson Foods. Wilson Sonsini Goodrich & Rosati advised Temasek on the transaction.
Client Highlights
10.14.21
Wilson Sonsini Represents Track 1099 in Its Acquisition by Avalara
On October 1, 2021, Avalara, a leading provider of tax compliance automation software for businesses of all sizes, announced it has acquired Track1099 LLC, a company that provides online software and services for cost-effectively managing, e-filing, and e-delivering IRS forms, including 1099s, W-2s, W-9s, and more. Wilson Sonsini Goodrich & Rosati represented Track1099 in the transaction.
Client Highlights
6.25.21
Wilson Sonsini Advises Temasek on Pear Therapeutics' Business Combination with Thimble Point Acquisition Corp.
On June 22, 2021, Pear Therapeutics, the leader in developing and commercializing prescription digital therapeutics to treat serious disease, and Thimble Point Acquisition Corp., a special purpose acquisition company whose management team is associated with the Pritzker Vlock Family Office, announced they have entered into a definitive business combination agreement. In addition, they announced a $125 million PIPE financing.
Client Highlights
6.22.21
Wilson Sonsini Advises InSilico Medicine on $255 Million Series C Financing
On June 22, 2021, Hong Kong-based InSilico Medicine, a global leader in end-to-end artificial intelligence for target discovery, small molecule chemistry, and clinical development, announced that it has closed a $255 million Series C financing led by Warburg Pincus. The financing included participation by current investors including Qiming Venture Partners, Pavilion Capital, Eight Roads Ventures, Lilly Asia Ventures, Sinovation Ventures, BOLD Capital Partners, Formic Ventures, and Baidu Ventures and new investors including CPE, Hillhouse Capital, OrbiMed, Mirae Asset, B Capital Group, Deerfield Management, Maison Capital, Lake Bleu Capital, President International Development Corporation, Sequoia Capital China, and Sage Partners.
Client Highlights
6.07.21
Firm Advises Temasek on Helix’s $50 Million Series C Funding
On June 3, 2021, Helix, the leading population genomics and COVID-19 testing company, announced that it has closed a $50 million Series C funding round led by existing investors Warburg Pincus, DFJ Growth, Kleiner Perkins Caufield Byers, Mayo Clinic, and Temasek. Wilson Sonsini Goodrich & Rosati advised Temasek on the transaction.
The proceeds from the financing will be used to accelerate Helix’s population genomics platform across health systems, life sciences companies, and payers, as well as power its growing COVID-19 testing and viral surveillance efforts. Helix's end-to-end genomics platform enables organizations to advance genomic research and accelerate the integration of genomic data into clinical care through its unique “Sequence Once, Query Often™” model. With this model, an individual's DNA can be collected, sequenced, and securely stored once, while allowing continuous access to the genomic data and insights as needed, without collecting additional saliva samples.
The Wilson Sonsini team that advised Temasek on the financing included:
The proceeds from the financing will be used to accelerate Helix’s population genomics platform across health systems, life sciences companies, and payers, as well as power its growing COVID-19 testing and viral surveillance efforts. Helix's end-to-end genomics platform enables organizations to advance genomic research and accelerate the integration of genomic data into clinical care through its unique “Sequence Once, Query Often™” model. With this model, an individual's DNA can be collected, sequenced, and securely stored once, while allowing continuous access to the genomic data and insights as needed, without collecting additional saliva samples.
The Wilson Sonsini team that advised Temasek on the financing included:
Client Highlights
3.31.21
Wilson Sonsini Advises Lifelink Systems on $9.75 Million Series A Funding
On March 30, 2021, Oakland, California-based Lifelink Systems announced that it has completed its Series A funding round, raising $9.75 million to accelerate the growth of its conversational AI technology for healthcare enterprises. The financing was led by DigiTx Partners and included Primera Capital, Baleon Capital, and inside investors. Wilson Sonsini Goodrich & Rosati advised Lifelink Systems on the transaction.
Lifelink Systems runs a conversational AI technology platform used by large healthcare provider systems and life sciences companies to improve the way they interact with patients. As part of advanced virtual care initiatives, patients use mobile chatbots from Lifelink Systems to schedule appointments, digitize paperwork, stay informed, and follow care plans. In January, the company announced that its platform was automating 850,000 conversations per month, putting it on track to surpass 10 million automated patient interactions per year.
The Wilson Sonsini team that advised Lifelink Systems on the financing included Barry Taylor, Alyssa Frederick, and Jacie Valentine.
Lifelink Systems runs a conversational AI technology platform used by large healthcare provider systems and life sciences companies to improve the way they interact with patients. As part of advanced virtual care initiatives, patients use mobile chatbots from Lifelink Systems to schedule appointments, digitize paperwork, stay informed, and follow care plans. In January, the company announced that its platform was automating 850,000 conversations per month, putting it on track to surpass 10 million automated patient interactions per year.
The Wilson Sonsini team that advised Lifelink Systems on the financing included Barry Taylor, Alyssa Frederick, and Jacie Valentine.
Client Highlights
3.03.21
Wilson Sonsini Represents WuXi AppTec in Acquisition of OXGENE
On March 2, 2021, WuXi AppTec, a leading global provider of R&D- and manufacturing-enabling services in the pharmaceutical, biotechnology, and medical device industries, announced that it has completed its acquisition of OXGENE, a pioneering United Kingdom-based contract research and development organization that designs and develops scalable gene therapy technologies. The acquisition enables WuXi AppTec to offer its customers end-to-end support in the creation and development of cutting-edge cell and gene therapies for patients in need worldwide. Wilson Sonsini Goodrich & Rosati represented WuXi AppTec in the transaction, in collaboration with Taylor Wessing, which served as UK counsel.
OXGENE will become a fully owned subsidiary of WuXi Advanced Therapies (WuXi ATU), WuXi AppTec’s cell and gene therapy contract testing, development, and manufacturing organization business unit. WuXi ATU's integrated platforms transform the development, testing, manufacturing, and commercialization of cell and gene therapy products and accelerate their time to market. OXGENE, which will retain its name, will be WuXi ATU's first facility in Europe and will further enhance these industry-leading capabilities.
The Wilson Sonsini team that represented WuXi AppTec in the transaction included the following:
Corporate
Barry Taylor
Kathy H. Ku
Nikkisha Smith
Rui Ke
London Corporate
Stacy Kim
Amanda Pollard
Jose Campos
OXGENE will become a fully owned subsidiary of WuXi Advanced Therapies (WuXi ATU), WuXi AppTec’s cell and gene therapy contract testing, development, and manufacturing organization business unit. WuXi ATU's integrated platforms transform the development, testing, manufacturing, and commercialization of cell and gene therapy products and accelerate their time to market. OXGENE, which will retain its name, will be WuXi ATU's first facility in Europe and will further enhance these industry-leading capabilities.
The Wilson Sonsini team that represented WuXi AppTec in the transaction included the following:
Corporate
Barry Taylor
Kathy H. Ku
Nikkisha Smith
Rui Ke
London Corporate
Stacy Kim
Amanda Pollard
Jose Campos
Client Highlights
2.03.21
Firm Advises Temasek on Pairwise’s $90 Million Series B Financing
On February 3, 2021, leading mission-driven food tech company Pairwise announced the close of a $90 million Series B financing. The funding for the round was led by Pontifax Global Food and Agriculture Technology Fund and Deerfield Management Company, with participation from new investor Temasek and existing investor Leaps by Bayer. Wilson Sonsini Goodrich & Rosati advised Temasek in the transaction.
Through its unique use of cutting-edge CRISPR technology, Pairwise aims to build a healthier world by introducing better fruits and vegetables with improved taste, enhanced convenience, increased shelf life, improved yield, simplified harvesting, or lengthened season availability. The company—which has built a crop trait development platform based on gene editing technology licensed from leading research organizations—believes the use of technology offers a transformative opportunity to open a new horizon for the $66 billion U.S. retail produce market, and is currently developing new types of leafy greens, berries, and cherries. Its first product is expected in 2022.
The Wilson Sonsini team that advised Temasek on the financing includes:
Corporate
Barry Taylor
Adam Bloom
Tax
Jonathan Zhu
Derek Wallace
Regulatory
Stephen Heifetz
Anne Seymour
For more information, please see Pairwise’s press release.
Through its unique use of cutting-edge CRISPR technology, Pairwise aims to build a healthier world by introducing better fruits and vegetables with improved taste, enhanced convenience, increased shelf life, improved yield, simplified harvesting, or lengthened season availability. The company—which has built a crop trait development platform based on gene editing technology licensed from leading research organizations—believes the use of technology offers a transformative opportunity to open a new horizon for the $66 billion U.S. retail produce market, and is currently developing new types of leafy greens, berries, and cherries. Its first product is expected in 2022.
The Wilson Sonsini team that advised Temasek on the financing includes:
Corporate
Barry Taylor
Adam Bloom
Tax
Jonathan Zhu
Derek Wallace
Regulatory
Stephen Heifetz
Anne Seymour
For more information, please see Pairwise’s press release.
Client Highlights
12.14.20
Wilson Sonsini Advises Temasek on Pear Therapeutics’ $80 Million Fundraise
On December 8, 2020, Pear Therapeutics announced that it has successfully closed an $80 million Series D financing led by SoftBank Vision Fund 2 with participation from existing investors, including Temasek, 5AM Ventures, Arboretum Ventures, JAZZ Venture Partners, Novartis, CrimsoNox, and EDBI, and new investors Forth Management, Pilot House, Sarissa Capital, Shanda Group, and QUAD Investment Management. Wilson Sonsini Goodrich & Rosati represented Temasek in the transaction.
Client Highlights
11.20.20
Wilson Sonsini Advises Leading Investors in US$200 Million Series A Financing of D3 Bio
On November 17, 2020, D3 Bio, Inc., a global biotechnology company, announced that it had entered into definitive agreements with respect to its US$200 million Series A financing led by Boyu Capital, Matrix Partners China, Sequoia Capital China, the corporate venture fund of WuXi AppTec, and certain other investors.
Client Highlights
10.29.20
Wilson Sonsini Advises Cognite in Agreement with Accel
On October 27, 2020, Cognite, a global leader in industrial software innovation headquartered in Norway, announced that it has signed a partnership agreement with leading global venture capital firm Accel. Coupled with Accel’s broad network and expertise in successfully scaling software companies, the partnership enables Cognite to accelerate its global growth initiatives across industrial verticals and expand go-to-market activities and product development. Additionally, as part of the agreement, Accel is gaining a seat on Cognite’s board of directors.